Figure 2From: Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinomaCharacterization of T cell responses. (A) CD8+CD107a+ effector cells, (B) CD8+perforin+ effector cells, (C) PD-1+ T cells, (D) CD4+CD25+FoxP3+ Tregs before and after treatment.Back to article page